Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free NHI Stock Alerts

National Health Investors (NHI) Financials

National Health Investors logo
$73.46 -1.80 (-2.39%)
Closing price 03:59 PM Eastern
Extended Trading
$73.46 -0.01 (-0.01%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for National Health Investors

Annual Income Statements for National Health Investors

This table shows National Health Investors' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 149 152 159 154 160 185 112 66 136 138 142
Consolidated Net Income / (Loss)		 150 153 159 154 160 185 112 66 134 137 141
Net Income / (Loss) Continuing Operations		 150 153 159 154 160 185 112 66 134 137 141
Total Pre-Tax Income 		150 153 159 154 160 188 112 66 134 136 137
Total Operating Income		 127 119 151 155 161 171 83 65 177 183 194
Total Gross Profit		 229 248 279 295 318 333 299 307 320 335 376
Total Revenue		 229 248 279 295 318 333 299 307 320 335 376
Operating Revenue		 229 248 279 295 318 333 299 307 320 335 376
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 102 130 127 140 157 162 216 242 143 152 182
Selling, General & Admin Expense		 11 9.77 12 13 13 13 18 23 19 21 27
Depreciation Expense		 53 60 67 71 77 83 81 71 70 71 81
Other Operating Expenses / (Income)		 38 60 47 55 66 64 117 148 53 60 72
Other Special Charges / (Income)		 0.46 0.42 0.49 0.31 0.51 1.25 - - 0.00 0.00 1.57
Total Other Income / (Expense), net		 23 35 7.87 -0.74 -0.82 17 29 0.96 -43 -47 -57
Interest Expense		 0.00 0.00 2.21 0.74 0.82 3.92 1.91 0.15 58 60 57
Other Income / (Expense), net		 25 36 10 0.00 0.00 21 32 1.11 15 13 0.46
Other Gains / (Losses), net		 - - - 0.00 0.00 -3.13 - 0.57 0.56 0.40 3.66
Net Income / (Loss) Attributable to Noncontrolling Interest		 1.45 1.18 0.00 0.00 -0.01 0.19 0.16 -0.90 -1.27 -1.35 -1.39
Basic Earnings per Share		 $3.96 $3.88 $3.90 $3.68 $3.70 $4.14 $2.45 $1.48 $3.13 $3.14 $3.03
Weighted Average Basic Shares Outstanding		 37.60M 39.01M 40.89M 41.94M 43.42M 44.70M 45.71M 44.77M 43.39M 43.84M 46.87M
Diluted Earnings per Share		 $3.95 $3.87 $3.87 $3.67 $3.67 $4.14 $2.44 $1.48 $3.13 $3.13 $3.02
Weighted Average Diluted Shares Outstanding		 37.64M 39.16M 41.15M 42.09M 43.70M 44.70M 45.73M 44.79M 43.39M 44.10M 47.05M
Weighted Average Basic & Diluted Shares Outstanding		 38.40M 39.85M 41.53M 42.74M 44.59M 45.19M 45.85M 43.39M 43.41M 45.69M 48.39M
Cash Dividends to Common per Share		 $3.40 $3.60 $3.80 $4.00 $4.20 $4.41 $3.80 $3.60 $3.60 - $3.48

Quarterly Income Statements for National Health Investors

This table shows National Health Investors' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 29 32 31 35 29 43 34 37 33 38 40
Consolidated Net Income / (Loss)		 29 32 31 35 28 43 34 37 32 38 40
Net Income / (Loss) Continuing Operations		 29 32 31 35 28 43 34 37 32 38 40
Total Pre-Tax Income 		29 31 31 35 28 43 33 35 32 36 40
Total Operating Income		 43 59 45 35 28 8.45 48 35 32 79 52
Total Gross Profit		 80 79 82 86 83 92 89 91 90 106 115
Total Revenue		 80 79 82 86 83 92 89 91 90 106 115
Operating Revenue		 80 79 82 86 83 92 89 91 90 106 115
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 37 21 36 52 55 84 42 56 58 27 63
Selling, General & Admin Expense		 4.43 4.93 5.64 4.87 4.81 5.41 6.83 6.13 6.31 7.60 7.85
Depreciation Expense		 18 17 18 17 18 19 19 20 20 22 24
Other Operating Expenses / (Income)		 15 -1.39 13 29 32 60 15 28 31 -2.51 31
Other Special Charges / (Income)		 - - 0.00 0.00 -0.10 - 0.26 1.31 0.00 - 0.00
Total Other Income / (Expense), net		 -14 -28 -15 0.00 0.00 34 -14 0.00 0.11 -43 -12
Interest Expense		 15 - 15 - - - 14 - - - 15
Other Income / (Expense), net		 0.94 1.02 0.10 - - 4.54 0.11 - 0.11 - 2.65
Other Gains / (Losses), net		 0.00 0.56 0.17 0.24 0.00 - 0.42 1.52 0.07 1.65 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.31 -0.33 -0.29 -0.30 -0.30 -0.45 -0.30 -0.30 -0.38 -0.36 -0.27
Basic Earnings per Share		 $0.68 $0.74 $0.71 $0.81 $0.66 $0.96 $0.75 $0.79 $0.69 $0.80 $0.83
Weighted Average Basic Shares Outstanding		 43.39M 43.39M 43.39M 43.40M 43.48M 43.84M 45.72M 46.69M 47.43M 46.87M 48.32M
Diluted Earnings per Share		 $0.68 $0.74 $0.71 $0.81 $0.65 $0.96 $0.74 $0.79 $0.69 $0.80 $0.82
Weighted Average Diluted Shares Outstanding		 43.39M 43.39M 43.42M 43.56M 43.99M 44.10M 45.88M 46.82M 47.62M 47.05M 48.55M
Weighted Average Basic & Diluted Shares Outstanding		 43.41M 43.41M 43.42M 43.44M 45.42M 45.69M 46.69M 47.47M 47.64M 48.39M 48.47M
Cash Dividends to Common per Share		 $0.90 - $0.90 $0.90 $0.90 - $0.90 $0.90 $0.92 - $0.92

Annual Cash Flow Statements for National Health Investors

This table details how cash moves in and out of National Health Investors' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 10.00 -9.04 -0.80 1.84 5.76 31 -6.86 -18 3.10 1.89 -6.88
Net Cash From Operating Activities		 164 177 198 208 241 232 211 185 184 208 237
Net Cash From Continuing Operating Activities		 168 177 198 208 240 231 211 185 184 208 237
Net Income / (Loss) Continuing Operations		 150 153 159 154 160 185 112 66 134 137 141
Consolidated Net Income / (Loss)		 150 153 159 154 160 185 112 66 134 137 141
Depreciation Expense		 53 60 67 71 77 83 81 71 70 71 81
Amortization Expense		 3.51 2.91 5.39 4.16 4.62 4.53 4.65 11 4.76 6.56 5.41
Non-Cash Adjustments To Reconcile Net Income		 -43 -39 -32 -21 -20 -35 14 41 -30 -7.12 2.16
Changes in Operating Assets and Liabilities, net		 3.76 0.16 -1.69 -0.57 19 -6.74 -0.44 -2.70 5.33 0.25 7.26
Net Cash From Investing Activities		 -136 -330 -164 -250 -343 -90 185 198 -12 -192 -269
Net Cash From Continuing Investing Activities		 -136 -330 -164 -250 -343 -90 185 198 -12 -192 -269
Purchase of Property, Plant & Equipment		 -109 -363 -176 -132 -219 -103 -47 -6.36 -38 -138 -274
Purchase of Investments		 -8.46 - - -16 -18 -14 -3.47 -4.63 -11 -20 -20
Sale of Property, Plant & Equipment		 - - - 0.00 0.00 40 239 169 57 6.18 0.00
Sale and/or Maturity of Investments		 57 60 18 - 0.00 0.00 1.21 0.57 3.06 0.40 3.66
Other Investing Activities, net		 -76 -20 -6.24 -103 -105 -12 -4.51 39 -22 -41 21
Net Cash From Financing Activities		 -18 144 -35 44 107 -112 -403 -401 -170 -14 26
Net Cash From Continuing Financing Activities		 -18 144 -35 44 107 -112 -403 -401 -170 -14 26
Repayment of Debt		 -343 -1.03 -462 -446 -182 -253 -693 -323 -579 -442 -1,026
Repurchase of Common Equity		 - - - - - 0.00 0.00 -152 0.00 -0.93 -0.77
Payment of Dividends		 -127 -140 -153 -165 -180 -195 -184 -163 -158 -158 -171
Issuance of Debt		 403 199 519 606 397 305 492 225 564 450 1,040
Issuance of Common Equity		 49 104 122 82 96 35 48 12 2.97 144 183
Other Financing Activities, net		 0.00 -18 -0.57 -1.84 -1.56 -2.71 0.00 -0.29 0.00 -5.82 -0.46
Cash Interest Paid		 31 40 43 46 54 43 44 43 52 55 51

Quarterly Cash Flow Statements for National Health Investors

This table details how cash moves in and out of National Health Investors' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.78 6.12 -11 3.57 0.86 8.74 111 -118 62 -62 5.32
Net Cash From Operating Activities		 50 53 41 61 49 58 46 60 63 68 53
Net Cash From Continuing Operating Activities		 50 53 41 61 49 58 46 60 63 68 53
Net Income / (Loss) Continuing Operations		 29 32 31 35 28 43 34 37 32 38 40
Consolidated Net Income / (Loss)		 29 32 31 35 28 43 34 37 32 38 40
Depreciation Expense		 18 17 18 17 18 19 19 20 20 22 24
Amortization Expense		 1.94 1.93 2.07 2.59 2.02 2.69 1.60 2.19 1.77 -0.85 1.51
Non-Cash Adjustments To Reconcile Net Income		 0.53 -2.21 2.18 -1.17 2.83 -11 0.36 -3.40 7.84 -2.63 -1.39
Changes in Operating Assets and Liabilities, net		 0.68 4.66 -12 6.88 -2.23 4.38 -8.46 4.43 0.23 12 -10
Net Cash From Investing Activities		 -20 2.34 -16 -13 -1.57 -161 -75 -48 42 -187 -104
Net Cash From Continuing Investing Activities		 -20 2.34 -16 -13 -1.57 -161 -75 -48 42 -187 -104
Purchase of Property, Plant & Equipment		 - - -2.98 -9.87 - -128 -74 -54 - -143 -105
Purchase of Investments		 -2.57 -2.26 - -2.75 -4.68 -6.02 -2.18 - -5.04 -10 -2.90
Sale of Property, Plant & Equipment		 2.92 5.49 - 4.66 - 1.52 0.00 - - - 6.66
Sale and/or Maturity of Investments		 - 0.56 0.17 0.24 - - 0.42 1.52 0.07 1.65 0.00
Other Investing Activities, net		 -20 -1.45 -13 -5.63 3.11 -28 0.78 9.28 47 -35 -2.17
Net Cash From Financing Activities		 -31 -49 -36 -44 -46 112 140 -129 -42 57 56
Net Cash From Continuing Financing Activities		 -31 -49 -36 -44 -46 112 140 -129 -42 57 56
Repayment of Debt		 -43 -91 -56 -65 -125 -197 -145 -213 -533 -135 -35
Repurchase of Common Equity		 - - 0.00 - - -0.15 -0.05 -0.11 - -0.61 0.00
Payment of Dividends		 -39 -39 -39 -39 -39 -40 -41 -42 -43 -44 -45
Issuance of Debt		 52 81 59 61 124 206 261 68 522 189 140
Issuance of Common Equity		 - 0.05 0.00 0.07 - 143 65 58 12 48 0.00
Other Financing Activities, net		 - - 0.00 - -5.42 - -0.13 -0.06 -0.22 -0.04 -4.50
Cash Interest Paid		 15 11 17 11 17 10 17 10 17 7.53 18

Annual Balance Sheets for National Health Investors

This table presents National Health Investors' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2,133 2,404 2,546 2,751 3,042 3,120 2,839 2,507 2,488 2,614 2,797
Total Current Assets		 86 4.64 3.06 4.66 5.22 43 37 19 22 24 20
Cash & Equivalents		 13 4.64 3.06 4.66 5.22 43 37 19 22 24 20
Plant, Property, & Equipment, net		 1,837 2,160 2,286 2,367 2,560 2,667 2,318 2,118 2,107 2,211 2,474
Plant, Property & Equipment, gross		 2,096 2,473 2,666 2,818 3,075 3,265 2,895 2,730 2,780 2,954 3,296
Accumulated Depreciation		 259 313 380 451 514 598 577 612 673 742 822
Total Noncurrent Assets		 210 2,724 257 379 477 410 484 327 359 379 304
Noncurrent Note & Lease Receivables		 193 133 141 246 340 292 300 233 245 269 203
Other Noncurrent Operating Assets		 17 2,590 116 133 136 117 184 93 109 110 97
Other Noncurrent Nonoperating Assets		 - - - - - - - 0.00 5.00 0.00 3.56
Total Liabilities & Shareholders' Equity		 2,133 2,404 2,546 2,751 3,042 3,120 2,839 2,507 2,488 2,614 2,797
Total Liabilities		 991 1,194 1,224 1,361 1,544 1,598 1,322 1,218 1,214 1,229 1,257
Total Current Liabilities		 20 21 16 63 26 25 23 26 34 83 93
Accounts Payable		 20 21 16 20 26 25 23 26 34 38 44
Dividends Payable		 - - - 43 - - - - - 41 44
Current Deferred Revenue		 - - - - - - - - - 4.28 5.00
Total Noncurrent Liabilities		 971 1,173 1,207 1,298 1,518 1,572 1,299 1,192 1,180 1,146 1,164
Long-Term Debt		 914 1,116 1,145 1,282 1,440 1,499 1,243 1,148 1,135 1,146 1,164
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - - 0.00 9.83 9.66 9.79 10
Total Equity & Noncontrolling Interests		 1,142 1,210 1,322 1,390 1,498 1,523 1,517 1,280 1,264 1,375 1,530
Total Preferred & Common Equity		 1,133 1,210 1,322 1,390 1,498 1,512 1,507 1,270 1,254 1,366 1,522
Total Common Equity		 1,133 1,210 1,322 1,390 1,498 1,512 1,507 1,270 1,254 1,366 1,522
Common Stock		 1,086 1,174 1,290 1,370 1,506 1,541 1,592 1,600 1,604 1,737 1,923
Retained Earnings		 20 30 33 - -5.33 - - -330 -350 -371 -402
Noncontrolling Interest		 9.17 - - 0.00 0.62 11 9.90 9.86 10 8.91 8.17

Quarterly Balance Sheets for National Health Investors

This table presents National Health Investors' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 2,509 2,533 2,498 2,499 2,478 2,477 2,460 2,783 2,696 2,690 2,890
Total Current Assets		 111 14 17 17 11 15 16 135 19 82 25
Cash & Equivalents		 29 14 17 17 11 15 16 135 19 82 25
Plant, Property, & Equipment, net		 2,141 2,165 2,135 2,120 2,093 2,106 2,097 2,270 2,316 2,303 2,555
Plant, Property & Equipment, gross		 2,737 2,791 2,774 2,777 2,783 2,812 2,820 3,032 3,098 3,104 3,399
Accumulated Depreciation		 599 626 639 656 691 706 724 761 781 802 844
Total Noncurrent Assets		 257 354 346 362 374 356 348 378 361 306 310
Noncurrent Note & Lease Receivables		 207 299 306 243 343 241 233 260 253 209 206
Other Noncurrent Operating Assets		 17 29 27 108 26 109 109 118 108 97 100
Other Noncurrent Nonoperating Assets		 33 27 13 11 5.00 5.67 5.67 - - - 3.56
Total Liabilities & Shareholders' Equity		 2,509 2,533 2,498 2,499 2,478 2,477 2,460 2,783 2,696 2,690 2,890
Total Liabilities		 1,182 1,245 1,208 1,218 1,211 1,213 1,213 1,338 1,199 1,192 1,357
Total Current Liabilities		 23 25 29 29 27 33 33 29 80 83 88
Accounts Payable		 23 25 29 29 27 33 33 29 33 35 38
Dividends Payable		 - - - - - - - - 43 44 45
Current Deferred Revenue		 - - - - - - - - 4.06 4.02 5.21
Total Noncurrent Liabilities		 1,159 1,220 1,179 1,189 1,184 1,180 1,180 1,309 1,119 1,109 1,270
Long-Term Debt		 1,115 1,176 1,135 1,144 1,139 1,136 1,136 1,263 1,119 1,109 1,270
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 11 9.52 10 9.92 9.43 9.17 8.93 9.54 9.32 9.03 9.92
Total Equity & Noncontrolling Interests		 1,315 1,279 1,280 1,271 1,258 1,254 1,238 1,435 1,488 1,489 1,523
Total Preferred & Common Equity		 1,306 1,267 1,269 1,260 1,248 1,244 1,229 1,426 1,480 1,481 1,515
Total Common Equity		 1,306 1,267 1,269 1,260 1,248 1,244 1,229 1,426 1,480 1,481 1,515
Common Stock		 1,598 1,602 1,602 1,603 1,606 1,607 1,602 1,805 1,864 1,876 1,921
Retained Earnings		 - -334 -333 -343 -358 -362 -373 -379 -384 -395 -406
Noncontrolling Interest		 9.08 12 11 11 10 9.89 9.53 8.57 8.33 8.57 7.84

Annual Metrics And Ratios for National Health Investors

This table displays calculated financial ratios and metrics derived from National Health Investors' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 28.98% 8.52% 12.15% 5.72% 7.97% 4.63% -10.24% 2.62% 4.34% 6.89% 12.07%
EBITDA Growth		 44.62% 4.38% 7.84% -1.52% 5.26% 15.38% -28.39% -26.37% 81.95% -19.20% 2.44%
EBIT Growth		 46.77% 2.18% 4.46% -4.03% 4.00% 19.28% -40.18% -42.83% 191.61% -28.99% -0.84%
NOPAT Growth		 23.46% -7.17% 28.18% 2.36% 4.00% 6.06% -51.72% -21.67% 173.83% -26.62% 5.91%
Net Income Growth		 45.86% 1.60% 4.35% -3.16% 3.96% 15.50% -39.58% -41.50% 105.16% 1.68% 3.04%
EPS Growth		 29.93% -2.03% 0.00% -5.17% 0.00% 12.81% -41.06% -39.34% 111.49% 0.00% -3.51%
Operating Cash Flow Growth		 30.35% 7.43% 12.15% 4.93% 0.00% 0.00% -9.17% -12.10% -0.48% 12.64% 13.86%
Free Cash Flow Firm Growth		 106.54% -9,912.14% 191.75% -103.60% 30.07% 300.09% 169.78% 21.62% -58.72% -97.18% 1.25%
Invested Capital Growth		 5.32% 143.83% -48.71% 9.94% 8.27% 1.55% -8.61% -12.77% 0.29% 5.26% 6.94%
Revenue Q/Q Growth		 5.98% 2.61% 2.24% 0.99% 2.65% -0.28% -3.74% 10.59% 2.83% 3.94% 4.10%
EBITDA Q/Q Growth		 18.36% 23.19% 7.74% -0.89% 3.02% 0.22% -15.36% -4.39% 28.11% 6.71% 25.53%
EBIT Q/Q Growth		 22.92% 33.72% 9.85% -1.49% 3.72% -0.34% -23.48% -6.55% 43.63% 9.06% 42.16%
NOPAT Q/Q Growth		 3.39% 2.39% 3.00% -1.49% 3.72% -0.57% -33.22% 85.54% 46.88% 6.38% 41.82%
Net Income Q/Q Growth		 21.58% -8.18% -2.08% -0.46% 3.19% -2.56% -21.50% -7.02% 28.94% 8.82% -3.42%
EPS Q/Q Growth		 18.98% -9.58% -3.25% -0.81% 2.23% -2.82% -22.04% -5.73% 28.28% 7.56% -5.03%
Operating Cash Flow Q/Q Growth		 6.96% 2.14% 2.49% -0.28% 0.00% 0.00% -1.06% -3.64% 3.85% 2.15% 4.49%
Free Cash Flow Firm Q/Q Growth		 105.57% -1,468.01% 289,050.12% -877.89% 68.25% 4.41% -0.54% -2.59% 65.24% -96.96% 124.29%
Invested Capital Q/Q Growth		 -1.46% 109.96% 1.21% 4.98% -0.02% -0.23% -1.67% -0.23% -0.67% 6.11% 6.04%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 90.85% 87.38% 84.03% 78.27% 76.31% 84.14% 67.13% 48.16% 83.99% 63.49% 74.77%
Operating Margin		 55.35% 47.80% 54.36% 52.64% 50.70% 51.39% 27.64% 21.10% 55.38% 38.02% 51.66%
EBIT Margin		 66.12% 62.26% 57.98% 52.64% 50.70% 57.80% 38.52% 21.46% 59.99% 39.85% 51.78%
Profit (Net Income) Margin		 65.65% 61.47% 57.19% 52.39% 50.44% 55.68% 37.48% 21.37% 42.02% 39.97% 37.48%
Tax Burden Percent		 100.47% 99.51% 100.00% 100.00% 100.00% 98.34% 100.31% 99.79% 100.57% 100.30% 102.67%
Interest Burden Percent		 98.83% 99.22% 98.63% 99.52% 99.49% 97.96% 97.00% 99.77% 69.65% 100.00% 70.50%
Effective Tax Rate		 -0.47% 0.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 6.63% 3.49% 4.17% 5.99% 5.72% 5.79% 2.90% 2.54% 7.45% 5.32% 7.36%
ROIC Less NNEP Spread (ROIC-NNEP)		 9.42% 5.05% 4.50% 5.93% 5.66% 6.77% 5.11% 2.61% 3.55% 5.92% 2.82%
Return on Net Nonoperating Assets (RNNOA)		 7.08% 9.50% 8.42% 5.39% 5.40% 6.48% 4.47% 2.13% 3.04% 4.96% 2.27%
Return on Equity (ROE)		 13.71% 12.99% 12.59% 11.38% 11.11% 12.27% 7.37% 4.67% 10.48% 10.28% 9.63%
Cash Return on Invested Capital (CROIC)		 1.44% -80.17% 68.57% -3.47% -2.23% 4.25% 11.89% 16.18% 7.16% 0.20% 0.65%
Operating Return on Assets (OROA)		 7.36% 6.82% 6.53% 5.86% 5.57% 6.24% 3.86% 2.46% 7.68% 5.34% 7.19%
Return on Assets (ROA)		 7.30% 6.73% 6.44% 5.83% 5.54% 6.01% 3.76% 2.45% 5.38% 5.36% 5.20%
Return on Common Equity (ROCE)		 13.59% 12.94% 12.59% 11.38% 11.11% 12.22% 7.32% 4.62% 10.32% 10.13% 9.50%
Return on Equity Simple (ROE_SIMPLE)		 13.26% 12.63% 12.05% 11.11% 10.71% 12.25% 7.43% 5.16% 10.72% 10.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 127 118 151 155 161 171 83 65 177 130 194
NOPAT Margin		 55.61% 47.57% 54.36% 52.64% 50.70% 51.39% 27.64% 21.10% 55.38% 38.02% 51.66%
Net Nonoperating Expense Percent (NNEP)		 -2.79% -1.56% -0.33% 0.06% 0.06% -0.99% -2.21% -0.07% 3.90% -0.60% 4.54%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 2.66% 7.38% 5.15% 7.20%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 4.59% 3.93% 4.38% 4.26% 4.21% 4.00% 6.17% 7.43% 6.04% 6.07% 7.15%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 44.65% 52.20% 45.64% 47.36% 49.30% 48.61% 72.36% 78.90% 44.62% 61.98% 48.34%
Earnings before Interest and Taxes (EBIT)		 151 155 162 155 161 192 115 66 192 136 194
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 208 217 234 231 243 280 201 148 269 217 281
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.22 1.56 1.59 1.62 1.78 1.64 1.49 1.58 1.84 2.30 2.39
Price to Tangible Book Value (P/TBV)		 1.22 1.56 1.59 1.62 1.78 1.64 1.49 1.58 1.84 2.30 2.39
Price to Revenue (P/Rev)		 6.05 7.57 7.52 7.66 8.40 7.46 7.52 6.55 7.20 9.21 9.69
Price to Earnings (P/E)		 9.31 12.42 13.16 14.63 16.65 13.41 20.09 30.24 16.97 22.83 25.59
Dividend Yield		 9.22% 7.62% 7.53% 7.48% 6.91% 7.94% 7.76% 7.78% 6.79% 5.19% 4.77%
Earnings Yield		 10.75% 8.05% 7.60% 6.83% 6.01% 7.46% 4.98% 3.31% 5.89% 4.38% 3.91%
Enterprise Value to Invested Capital (EV/IC)		 1.13 0.62 1.31 1.30 1.40 1.33 1.27 1.33 1.44 1.71 1.76
Enterprise Value to Revenue (EV/Rev)		 9.71 12.05 11.62 12.00 12.91 11.87 11.59 10.29 10.74 12.54 12.78
Enterprise Value to EBITDA (EV/EBITDA)		 10.69 13.79 13.83 15.33 16.92 14.10 17.26 21.37 12.78 19.76 17.09
Enterprise Value to EBIT (EV/EBIT)		 14.68 19.35 20.05 22.80 25.47 20.53 30.08 47.96 17.90 31.48 24.68
Enterprise Value to NOPAT (EV/NOPAT)		 17.46 25.33 21.38 22.80 25.47 23.09 41.92 48.79 19.39 32.99 24.74
Enterprise Value to Operating Cash Flow (EV/OCF)		 13.52 16.95 16.35 17.01 0.00 17.01 16.42 17.03 18.62 20.64 20.29
Enterprise Value to Free Cash Flow (EV/FCFF)		 80.29 0.00 1.30 0.00 0.00 31.43 10.21 7.65 20.18 894.49 280.55
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.80 0.92 0.87 0.92 0.96 0.98 0.82 0.89 0.89 0.83 0.76
Long-Term Debt to Equity		 0.80 0.92 0.87 0.92 0.96 0.98 0.82 0.89 0.89 0.83 0.76
Financial Leverage		 0.75 1.88 1.87 0.91 0.95 0.96 0.88 0.82 0.86 0.84 0.80
Leverage Ratio		 1.88 1.93 1.96 1.95 2.01 2.04 1.96 1.90 1.95 1.92 1.85
Compound Leverage Factor		 1.86 1.91 1.93 1.94 2.00 2.00 1.90 1.90 1.36 1.92 1.30
Debt to Total Capital		 44.46% 47.99% 46.42% 47.98% 49.02% 49.61% 45.03% 47.08% 47.12% 45.28% 43.04%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 44.46% 47.99% 46.42% 47.98% 49.02% 49.61% 45.03% 47.08% 47.12% 45.28% 43.04%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.45% 0.00% 0.00% 0.00% 0.02% 0.35% 0.36% 0.81% 0.83% 0.74% 0.68%
Common Equity to Total Capital		 55.10% 52.01% 53.58% 52.02% 50.96% 50.04% 54.61% 52.11% 52.05% 53.98% 56.28%
Debt to EBITDA		 4.40 5.14 4.89 5.56 5.93 5.35 6.20 7.77 4.23 5.28 4.14
Net Debt to EBITDA		 3.98 5.12 4.88 5.54 5.91 5.20 6.01 7.64 4.14 5.17 4.07
Long-Term Debt to EBITDA		 4.40 5.14 4.89 5.56 5.93 5.35 6.20 7.77 4.23 5.28 4.14
Debt to NOPAT		 7.18 9.44 7.56 8.27 8.93 8.77 15.05 17.74 6.41 8.82 6.00
Net Debt to NOPAT		 6.51 9.40 7.54 8.24 8.90 8.51 14.60 17.44 6.28 8.63 5.90
Long-Term Debt to NOPAT		 7.18 9.44 7.56 8.27 8.93 8.77 15.05 17.74 6.41 8.82 6.00
Altman Z-Score		 1.23 1.27 1.36 1.26 1.31 1.25 1.26 1.01 1.32 1.63 1.87
Noncontrolling Interest Sharing Ratio		 0.87% 0.39% 0.00% 0.00% 0.02% 0.38% 0.68% 1.05% 1.55% 1.46% 1.27%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.27 0.22 0.19 0.07 0.20 1.72 1.61 0.74 0.65 0.64 0.21
Quick Ratio		 4.27 0.22 0.19 0.07 0.20 1.72 1.61 0.74 0.65 0.64 0.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 28 -2,716 2,492 -90 -63 126 339 412 170 4.79 17
Operating Cash Flow to CapEx		 150.20% 48.71% 112.69% 157.77% 0.00% 368.02% 0.00% 0.00% 0.00% 157.46% 86.32%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 1,125.78 -121.69 -76.31 32.02 177.31 2,730.53 2.92 0.00 0.30
Operating Cash Flow to Interest Expense		 0.00 0.00 89.47 281.67 0.00 59.16 110.28 1,227.42 3.17 0.00 4.12
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 10.07 103.13 0.00 43.09 210.72 2,304.20 3.49 0.00 -0.65
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.11 0.11 0.11 0.11 0.11 0.11 0.10 0.11 0.13 0.13 0.14
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.13 0.12 0.13 0.13 0.13 0.13 0.12 0.14 0.15 0.16 0.16
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,971 4,806 2,465 2,709 2,934 2,979 2,722 2,375 2,382 2,507 2,725
Invested Capital Turnover		 0.12 0.07 0.08 0.11 0.11 0.11 0.10 0.12 0.13 0.14 0.14
Increase / (Decrease) in Invested Capital		 100 2,835 -2,341 245 224 45 -256 -348 6.92 125 177
Enterprise Value (EV)		 2,223 2,993 3,239 3,535 4,108 3,949 3,462 3,156 3,434 4,288 4,801
Market Capitalization		 1,385 1,882 2,097 2,258 2,672 2,483 2,246 2,008 2,301 3,148 3,638
Book Value per Share		 $30.17 $30.36 $31.83 $32.91 $34.07 $33.81 $32.87 $29.28 $28.89 $30.08 $31.94
Tangible Book Value per Share		 $30.17 $30.36 $31.83 $32.91 $34.07 $33.81 $32.87 $29.28 $28.89 $30.08 $31.94
Total Capital		 2,057 2,326 2,468 2,671 2,939 3,022 2,760 2,437 2,409 2,531 2,704
Total Debt		 914 1,116 1,145 1,282 1,440 1,499 1,243 1,148 1,135 1,146 1,164
Total Long-Term Debt		 914 1,116 1,145 1,282 1,440 1,499 1,243 1,148 1,135 1,146 1,164
Net Debt		 828 1,111 1,142 1,277 1,435 1,456 1,205 1,128 1,113 1,122 1,144
Capital Expenditures (CapEx)		 109 363 176 132 219 63 -192 -163 -19 132 274
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -20 -21 -16 -63 -26 -25 -23 -26 -34 -38 -93
Debt-free Net Working Capital (DFNWC)		 66 -16 -13 -58 -21 18 14 -6.61 -12 -13 -74
Net Working Capital (NWC)		 66 -16 -13 -58 -21 18 14 -6.61 -12 -13 -74
Net Nonoperating Expense (NNE)		 -23 -35 -7.87 0.74 0.82 -14 -29 -0.82 43 -6.66 53
Net Nonoperating Obligations (NNO)		 828 3,596 1,142 1,320 1,435 1,456 1,205 1,085 1,108 1,122 1,185
Total Depreciation and Amortization (D&A)		 57 62 73 76 81 88 85 82 77 81 86
Debt-free, Cash-free Net Working Capital to Revenue		 -8.80% -8.40% -5.85% -21.24% -8.27% -7.57% -7.76% -8.45% -10.73% -11.04% -24.80%
Debt-free Net Working Capital to Revenue		 28.78% -6.54% -4.75% -19.66% -6.63% 5.46% 4.76% -2.16% -3.74% -3.94% -19.58%
Net Working Capital to Revenue		 28.78% -6.54% -4.75% -19.66% -6.63% 5.46% 4.76% -2.16% -3.74% -3.94% -19.58%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $3.96 $3.88 $3.90 $3.68 $3.70 $4.14 $2.45 $1.48 $3.13 $3.14 $3.03
Adjusted Weighted Average Basic Shares Outstanding		 37.60M 39.01M 40.89M 41.94M 43.42M 44.70M 45.71M 44.77M 43.39M 43.84M 46.87M
Adjusted Diluted Earnings per Share		 $3.95 $3.87 $3.87 $3.67 $3.67 $4.14 $2.44 $1.48 $3.13 $3.13 $3.02
Adjusted Weighted Average Diluted Shares Outstanding		 37.64M 39.16M 41.15M 42.09M 43.70M 44.70M 45.73M 44.79M 43.39M 44.10M 47.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 38.40M 39.85M 41.53M 42.74M 44.59M 45.19M 45.85M 43.39M 43.41M 45.69M 48.39M
Normalized Net Operating Profit after Tax (NOPAT)		 89 119 106 109 113 121 58 45 124 91 137
Normalized NOPAT Margin		 38.89% 47.74% 38.18% 36.92% 35.60% 36.24% 19.35% 14.77% 38.76% 26.61% 36.45%
Pre Tax Income Margin		 65.35% 61.77% 57.19% 52.39% 50.44% 56.62% 37.37% 21.41% 41.78% 39.85% 36.51%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 72.98 210.12 195.96 49.02 60.19 435.72 3.29 0.00 3.39
NOPAT to Interest Expense		 0.00 0.00 68.42 210.12 195.96 43.59 43.19 428.34 3.04 0.00 3.38
EBIT Less CapEx to Interest Expense		 0.00 0.00 -6.42 31.59 -70.37 32.95 160.63 1,512.50 3.62 0.00 -1.39
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -10.98 31.59 -70.37 27.51 143.63 1,505.13 3.37 0.00 -1.40
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 84.46% 91.59% 96.03% 107.17% 112.03% 105.41% 164.16% 248.37% 117.22% 115.39% 121.19%
Augmented Payout Ratio		 84.46% 91.59% 96.03% 107.17% 112.03% 105.41% 164.16% 480.46% 117.22% 116.07% 121.73%

Quarterly Metrics And Ratios for National Health Investors

This table displays calculated financial ratios and metrics derived from National Health Investors' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 48,392,384.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 48,392,384.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.83
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 4.99% -19.74% -1.06% 9.11% 3.54% 16.32% 9.55% 4.95% 8.32% 25.49% 28.93%
EBITDA Growth		 20.37% 282.00% -5.54% -4.81% -0.96% -56.44% 6.53% 4.52% 13.24% 6.66% 16.79%
EBIT Growth		 28.89% 2,535.01% -10.80% -7.71% -2.13% -78.28% 5.19% 1.29% 14.74% 5.33% 14.77%
NOPAT Growth		 122.92% 92.03% -7.30% 13.53% -0.23% -85.63% 5.17% 1.29% 14.34% 5.33% 9.49%
Net Income Growth		 -15.18% 1,933.21% -10.32% -11.40% -2.72% 34.90% 10.31% 4.97% 15.00% -11.65% 17.55%
EPS Growth		 -12.82% 1,380.00% -10.13% -11.96% -4.41% 29.73% 4.23% -2.47% 6.15% -16.67% 10.81%
Operating Cash Flow Growth		 14.17% 14.77% 31.50% 20.28% -2.16% 8.21% 13.84% -1.52% 28.59% 17.65% 14.98%
Free Cash Flow Firm Growth		 -93.72% -86.28% -64.14% -2.31% 206.29% -324.92% -270.53% -549.65% -375.30% -7.26% -43.97%
Invested Capital Growth		 0.74% 0.29% -1.39% -0.65% -1.47% 5.26% 7.62% 10.98% 8.77% 6.94% 9.55%
Revenue Q/Q Growth		 2.86% -0.80% 2.58% 4.24% -2.38% 11.44% -3.39% 1.65% -1.02% 17.66% 8.91%
EBITDA Q/Q Growth		 -13.11% 24.07% 39.83% 39.11% -9.59% -45.43% 101.34% -17.22% -5.03% 83.44% -19.82%
EBIT Q/Q Growth		 -17.86% 35.64% 81.85% 62.57% -12.89% -69.91% 267.26% -26.32% -7.85% 143.69% -30.61%
NOPAT Q/Q Growth		 2.01% 36.23% 92.98% 58.12% -10.35% -80.38% 463.24% -26.14% -8.17% 144.54% -33.97%
Net Income Q/Q Growth		 -26.40% 9.25% -3.35% 14.01% -19.20% 51.50% -20.97% 8.49% -11.48% 16.40% 5.16%
EPS Q/Q Growth		 -26.09% 8.82% -4.05% 14.08% -19.75% 47.69% -22.92% 6.76% -12.66% 15.94% 2.50%
Operating Cash Flow Q/Q Growth		 -1.57% 7.04% -23.26% 48.77% -19.94% 18.39% -19.27% 28.70% 4.54% 8.32% -21.11%
Free Cash Flow Firm Q/Q Growth		 -60.68% 102.76% 625.04% -0.61% 23.28% -248.89% -15.21% -68.03% 22.57% 44.02% -97.63%
Invested Capital Q/Q Growth		 0.13% -0.67% 0.37% -0.48% -0.70% 6.11% 2.62% 2.63% -2.67% 6.04% 3.43%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 79.37% 99.26% 61.42% 81.97% 75.92% 37.18% 77.48% 63.09% 60.54% 94.38% 69.48%
Operating Margin		 53.90% 74.02% 37.28% 56.55% 51.94% 9.15% 53.32% 38.74% 35.94% 74.70% 45.29%
EBIT Margin		 55.08% 75.30% 37.41% 58.34% 52.06% 14.06% 53.45% 38.74% 36.07% 74.70% 47.59%
Profit (Net Income) Margin		 36.24% 39.91% 37.61% 41.13% 34.05% 46.29% 37.87% 40.42% 36.15% 35.76% 34.53%
Tax Burden Percent		 100.00% 102.45% 100.54% 100.68% 100.00% 100.00% 101.28% 104.33% 100.23% 104.53% 100.00%
Interest Burden Percent		 65.81% 51.74% 100.00% 70.03% 65.40% 329.27% 69.96% 100.00% 100.00% 45.80% 72.55%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 7.02% 9.95% 4.94% 7.73% 7.18% 1.28% 7.51% 5.46% 5.26% 10.64% 6.75%
ROIC Less NNEP Spread (ROIC-NNEP)		 5.71% 7.48% 4.96% 6.55% 5.85% 4.36% 6.29% 5.60% 5.28% 7.14% 5.72%
Return on Net Nonoperating Assets (RNNOA)		 4.76% 6.40% 4.39% 5.69% 5.16% 3.65% 5.22% 4.58% 4.20% 5.73% 4.64%
Return on Equity (ROE)		 11.78% 16.35% 9.33% 13.41% 12.34% 4.93% 12.73% 10.04% 9.46% 16.37% 11.38%
Cash Return on Invested Capital (CROIC)		 4.31% 7.16% 6.24% 5.77% 6.62% 0.20% -2.01% -5.12% -2.86% 0.65% -1.75%
Operating Return on Assets (OROA)		 6.84% 9.64% 4.76% 7.65% 6.91% 1.88% 7.10% 5.30% 5.05% 10.37% 6.74%
Return on Assets (ROA)		 4.50% 5.11% 4.79% 5.39% 4.52% 6.20% 5.03% 5.53% 5.07% 4.96% 4.89%
Return on Common Equity (ROCE)		 11.59% 16.10% 9.18% 13.20% 12.15% 4.86% 12.55% 9.91% 9.34% 16.16% 11.25%
Return on Equity Simple (ROE_SIMPLE)		 8.27% 0.00% 10.49% 10.15% 10.22% 0.00% 9.80% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 43 59 30 48 43 8.45 48 35 32 79 52
NOPAT Margin		 53.90% 74.02% 37.28% 56.55% 51.94% 9.15% 53.32% 38.74% 35.94% 74.70% 45.29%
Net Nonoperating Expense Percent (NNEP)		 1.30% 2.47% -0.02% 1.18% 1.33% -3.08% 1.23% -0.14% -0.02% 3.51% 1.03%
Return On Investment Capital (ROIC_SIMPLE)		 - 2.45% - - - 0.34% 1.76% 1.35% 1.24% 2.93% 1.87%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 5.53% 6.20% 6.92% 5.73% 5.80% 5.86% 7.65% 6.75% 7.02% 7.19% 6.82%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 46.10% 25.98% 62.72% 43.45% 48.06% 90.85% 46.68% 61.26% 64.06% 25.30% 54.71%
Earnings before Interest and Taxes (EBIT)		 44 60 30 50 43 13 48 35 32 79 55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 64 79 50 70 63 34 69 57 54 100 80
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.68 1.84 0.00 2.36 2.97 2.30 2.37 2.21 2.55 2.39 2.58
Price to Tangible Book Value (P/TBV)		 1.68 1.84 0.00 2.36 2.97 2.30 2.37 2.21 2.55 2.39 2.58
Price to Revenue (P/Rev)		 6.79 7.20 0.00 9.02 11.10 9.21 9.65 9.25 10.46 9.69 9.75
Price to Earnings (P/E)		 20.01 16.97 0.00 23.05 28.80 22.83 23.92 22.93 25.66 25.59 26.42
Dividend Yield		 7.40% 6.79% 5.81% 5.32% 4.28% 5.19% 4.87% 5.13% 4.55% 4.77% 4.53%
Earnings Yield		 5.00% 5.89% 0.00% 4.34% 3.47% 4.38% 4.18% 4.36% 3.90% 3.91% 3.79%
Enterprise Value to Invested Capital (EV/IC)		 1.36 1.44 0.00 1.72 2.03 1.71 1.76 1.66 1.88 1.76 1.84
Enterprise Value to Revenue (EV/Rev)		 10.48 10.74 0.00 12.52 14.57 12.54 12.93 12.41 13.36 12.78 12.89
Enterprise Value to EBITDA (EV/EBITDA)		 15.54 12.78 0.00 20.01 23.56 19.76 20.43 20.19 21.54 17.09 17.70
Enterprise Value to EBIT (EV/EBIT)		 24.40 17.90 0.00 32.43 38.35 31.48 32.62 33.08 35.22 24.68 25.68
Enterprise Value to NOPAT (EV/NOPAT)		 27.03 19.39 0.00 33.38 39.21 32.99 34.16 33.08 35.22 24.74 26.07
Enterprise Value to Operating Cash Flow (EV/OCF)		 18.35 18.62 0.00 19.96 23.55 20.64 21.18 20.67 21.29 20.29 21.25
Enterprise Value to Free Cash Flow (EV/FCFF)		 31.65 20.18 0.00 29.61 30.42 894.49 0.00 0.00 0.00 280.55 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.89 0.89 0.90 0.90 0.91 0.83 0.87 0.75 0.74 0.76 0.83
Long-Term Debt to Equity		 0.89 0.89 0.90 0.90 0.91 0.83 0.87 0.75 0.74 0.76 0.83
Financial Leverage		 0.83 0.86 0.88 0.87 0.88 0.84 0.83 0.82 0.80 0.80 0.81
Leverage Ratio		 1.92 1.95 1.96 1.95 1.96 1.92 1.94 1.87 1.88 1.85 1.91
Compound Leverage Factor		 1.26 1.01 1.96 1.36 1.28 6.32 1.36 1.87 1.88 0.85 1.38
Debt to Total Capital		 47.19% 47.12% 47.33% 47.34% 47.67% 45.28% 46.65% 42.77% 42.53% 43.04% 45.31%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 47.19% 47.12% 47.33% 47.34% 47.67% 45.28% 46.65% 42.77% 42.53% 43.04% 45.31%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.85% 0.83% 0.81% 0.79% 0.77% 0.74% 0.67% 0.67% 0.67% 0.68% 0.63%
Common Equity to Total Capital		 51.96% 52.05% 51.85% 51.86% 51.56% 53.98% 52.68% 56.56% 56.79% 56.28% 54.06%
Debt to EBITDA		 5.46 4.23 5.49 5.57 5.59 5.28 5.71 5.14 4.96 4.14 4.34
Net Debt to EBITDA		 5.38 4.14 5.43 5.50 5.51 5.17 5.10 5.06 4.59 4.07 4.26
Long-Term Debt to EBITDA		 5.46 4.23 5.49 5.57 5.59 5.28 5.71 5.14 4.96 4.14 4.34
Debt to NOPAT		 9.49 6.41 9.77 9.29 9.30 8.82 9.55 8.43 8.11 6.00 6.39
Net Debt to NOPAT		 9.35 6.28 9.68 9.17 9.17 8.63 8.52 8.29 7.51 5.90 6.27
Long-Term Debt to NOPAT		 9.49 6.41 9.77 9.29 9.30 8.82 9.55 8.43 8.11 6.00 6.39
Altman Z-Score		 1.02 1.14 0.00 1.44 1.78 1.48 1.55 1.59 1.87 1.73 1.71
Noncontrolling Interest Sharing Ratio		 1.59% 1.55% 1.59% 1.58% 1.55% 1.46% 1.39% 1.33% 1.31% 1.27% 1.20%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.57 0.65 0.42 0.44 0.48 0.64 4.63 0.23 0.99 0.21 0.28
Quick Ratio		 0.57 0.65 0.42 0.44 0.48 0.64 4.63 0.23 0.99 0.21 0.28
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 26 52 64 64 78 -117 -134 -226 -175 -98 -194
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 1,166.26% 0.00% 45.43% 60.62% 110.13% 0.00% 47.34% 54.07%
Free Cash Flow to Firm to Interest Expense		 1.70 0.00 0.00 4.28 5.25 0.00 -9.38 0.00 0.00 0.00 -12.87
Operating Cash Flow to Interest Expense		 3.29 0.00 0.00 4.09 3.26 0.00 3.24 0.00 0.00 0.00 3.55
Operating Cash Flow Less CapEx to Interest Expense		 3.49 0.00 0.00 3.74 3.26 0.00 -2.11 0.00 0.00 0.00 -3.02
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.12 0.13 0.13 0.13 0.13 0.13 0.13 0.14 0.14 0.14 0.14
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.15 0.15 0.15 0.15 0.16 0.16 0.16 0.16 0.16 0.16 0.17
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2,398 2,382 2,390 2,379 2,362 2,507 2,573 2,640 2,570 2,725 2,818
Invested Capital Turnover		 0.13 0.13 0.13 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.15
Increase / (Decrease) in Invested Capital		 18 6.92 -34 -16 -35 125 182 261 207 177 246
Enterprise Value (EV)		 3,259 3,434 0.00 4,081 4,791 4,288 4,521 4,392 4,819 4,801 5,175
Market Capitalization		 2,111 2,301 0.00 2,941 3,652 3,148 3,375 3,274 3,774 3,638 3,913
Book Value per Share		 $29.03 $28.89 $28.76 $28.66 $28.29 $30.08 $31.22 $31.69 $31.19 $31.94 $31.30
Tangible Book Value per Share		 $29.03 $28.89 $28.76 $28.66 $28.29 $30.08 $31.22 $31.69 $31.19 $31.94 $31.30
Total Capital		 2,425 2,409 2,407 2,400 2,384 2,531 2,708 2,616 2,608 2,704 2,802
Total Debt		 1,144 1,135 1,139 1,136 1,136 1,146 1,263 1,119 1,109 1,164 1,270
Total Long-Term Debt		 1,144 1,135 1,139 1,136 1,136 1,146 1,263 1,119 1,109 1,164 1,270
Net Debt		 1,128 1,113 1,128 1,121 1,121 1,122 1,128 1,100 1,027 1,144 1,245
Capital Expenditures (CapEx)		 -2.92 -5.49 0.00 5.21 0.00 127 77 54 0.00 143 99
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -29 -34 -27 -33 -33 -38 -29 -80 -83 -93 -88
Debt-free Net Working Capital (DFNWC)		 -13 -12 -15 -18 -17 -13 106 -61 -0.88 -74 -63
Net Working Capital (NWC)		 -13 -12 -15 -18 -17 -13 106 -61 -0.88 -74 -63
Net Nonoperating Expense (NNE)		 14 27 -0.27 13 15 -34 14 -1.52 -0.19 41 12
Net Nonoperating Obligations (NNO)		 1,117 1,108 1,123 1,116 1,115 1,122 1,128 1,143 1,071 1,185 1,286
Total Depreciation and Amortization (D&A)		 19 19 20 20 20 21 21 22 22 21 25
Debt-free, Cash-free Net Working Capital to Revenue		 -9.43% -10.73% -8.40% -10.18% -9.88% -11.04% -8.35% -22.56% -22.86% -24.80% -21.84%
Debt-free Net Working Capital to Revenue		 -4.10% -3.74% -4.84% -5.65% -5.16% -3.94% 30.26% -17.29% -0.24% -19.58% -15.62%
Net Working Capital to Revenue		 -4.10% -3.74% -4.84% -5.65% -5.16% -3.94% 30.26% -17.29% -0.24% -19.58% -15.62%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.68 $0.74 $0.71 $0.81 $0.66 $0.96 $0.75 $0.79 $0.69 $0.80 $0.83
Adjusted Weighted Average Basic Shares Outstanding		 43.39M 43.39M 43.39M 43.40M 43.48M 43.84M 45.72M 46.69M 47.43M 46.87M 48.32M
Adjusted Diluted Earnings per Share		 $0.68 $0.74 $0.71 $0.81 $0.65 $0.96 $0.74 $0.79 $0.69 $0.80 $0.82
Adjusted Weighted Average Diluted Shares Outstanding		 43.39M 43.39M 43.42M 43.56M 43.99M 44.10M 45.88M 46.82M 47.62M 47.05M 48.55M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 43.41M 43.41M 43.42M 43.44M 45.42M 45.69M 46.69M 47.47M 47.64M 48.39M 48.47M
Normalized Net Operating Profit after Tax (NOPAT)		 30 41 21 34 30 5.92 34 26 23 55 37
Normalized NOPAT Margin		 37.73% 51.82% 26.10% 39.59% 36.36% 6.40% 37.53% 28.13% 25.16% 52.29% 31.70%
Pre Tax Income Margin		 36.24% 38.96% 37.41% 40.86% 34.05% 46.29% 37.39% 38.74% 36.07% 34.21% 34.53%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 2.92 0.00 0.00 3.34 2.89 0.00 3.33 0.00 0.00 0.00 3.64
NOPAT to Interest Expense		 2.86 0.00 0.00 3.24 2.88 0.00 3.32 0.00 0.00 0.00 3.47
EBIT Less CapEx to Interest Expense		 3.12 0.00 0.00 2.99 2.89 0.00 -2.02 0.00 0.00 0.00 -2.93
NOPAT Less CapEx to Interest Expense		 3.06 0.00 0.00 2.88 2.88 0.00 -2.03 0.00 0.00 0.00 -3.10
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 151.01% 117.22% 120.30% 124.62% 125.36% 115.39% 114.29% 114.93% 114.00% 121.19% 118.53%
Augmented Payout Ratio		 151.05% 117.22% 120.30% 124.62% 125.98% 116.07% 114.99% 115.69% 114.20% 121.73% 119.02%

Financials Breakdown Chart

Key Financial Trends

National Health Investors (NYSE: NHI) shows a trend of growing revenue and improving cash generation in 2024–2025, with stable dividends and roughly steady leverage. The quarterly data indicate a higher base of assets and equity over the period, financed in part by debt issuances and ongoing capital expenditure to support portfolio growth. Below are the most relevant trends for retail investors to consider based on the last four years of quarterly statements.

  • Operating revenue in Q4 2025 was 105.7 million, up from 99.0 million in Q4 2024 and 79.5 million in Q4 2023, signaling a multi-year growth trend in core income.
  • Net cash from continuing operating activities rose through 2025 (about 46.5 million in Q1 2025 to 67.7 million in Q4 2025), indicating improved cash generation from operations.
  • Common dividend per share remained around 0.92 USD across 2025 quarters (0.92 in Q2–Q4 2025; ~0.90–0.92 in other periods), reflecting a stable payout policy for a REIT investor.
  • Long-term debt stayed in a modest, stable range around 1.1–1.14 billion across 2024–2025, suggesting manageable leverage rather than escalating debt loads.
  • Total equity including noncontrolling interests was around 1.28–1.49 billion in 2025, indicating a strengthening capital base to support value growth and financing needs.
  • Current assets and current liabilities were roughly balanced in mid-2025 (e.g., around 81.6 million current assets vs. about 82.5 million current liabilities in Q3 2025), implying a modest short-term liquidity cushion.
  • Investing activities show meaningful cash outflows tied to capital expenditure, consistent with ongoing property, plant & equipment investments (e.g., PPE purchases of about 532.6 million in Q3 2025 and 143.1 million in Q4 2025).
  • Financing activities fluctuate between net inflows and outflows as the company raises capital and repays debt, reflecting an active balance between debt and equity financing to fund growth.
  • Investing cash outflows were exceptionally large in certain quarters (e.g., PPE purchases of about 532.6 million in Q3 2025), which compresses cash despite solid operating cash flow.
  • Net change in cash was negative in Q4 2025 due to the combination of large capex and debt movements, despite positive operating cash flow (net cash change around -62.0 million).
05/11/26 02:56 PM ETAI Generated. May Contain Errors.

National Health Investors Financials - Frequently Asked Questions

According to the most recent income statement we have on file, National Health Investors' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

National Health Investors' net income appears to be on a downward trend, with a most recent value of $140.79 million in 2025, falling from $150.31 million in 2015. The previous period was $136.64 million in 2024. See where experts think National Health Investors is headed by visiting National Health Investors' forecast page.

National Health Investors' total operating income in 2025 was $194.04 million, based on the following breakdown:
  • Total Gross Profit: $375.63 million
  • Total Operating Expenses: $181.59 million

Over the last 10 years, National Health Investors' total revenue changed from $228.95 million in 2015 to $375.63 million in 2025, a change of 64.1%.

National Health Investors' total liabilities were at $1.26 billion at the end of 2025, a 2.3% increase from 2024, and a 26.9% increase since 2015.

In the past 10 years, National Health Investors' cash and equivalents has ranged from $3.06 million in 2017 to $43.34 million in 2020, and is currently $19.62 million as of their latest financial filing in 2025.

Over the last 10 years, National Health Investors' book value per share changed from 30.17 in 2015 to 31.94 in 2025, a change of 5.9%.


Related Companies

Financial statements for NYSE:NHI last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel